General Hospital of Thessaloniki ""George Papanikolaou""
- Address
- Exohi Papanikolaou Avenue, 57010 Thessaloniki, Greece
General Hospital of Thessaloniki George Papanikolaou - Hematologic Malignancies Research Center
The General Hospital of Thessaloniki George Papanikolaou is a leading clinical research institution specializing in hematologic malignancies, with particular expertise in multiple myeloma treatment and research. The center focuses on investigating novel therapeutic approaches for blood cancers, including advanced maintenance therapy strategies following stem cell transplantation.
- Newly Diagnosed Multiple Myeloma (NDMM) treatment protocols
- Post-transplant maintenance therapy optimization
- Novel immunomodulatory drug development and comparative effectiveness studies
The research center's clinical trial portfolio demonstrates a strong commitment to advancing treatment paradigms in multiple myeloma, particularly through comparative efficacy studies of next-generation therapies such as iberdomide versus standard lenalidomide maintenance following autologous stem cell transplantation (ASCT). This work aims to improve progression-free survival outcomes and establish evidence-based maintenance strategies for patients with newly diagnosed disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Celgene Corp.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital of Thessaloniki ""George Papanikolaou""
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) | Celgene Corp. | Phase III | Recruiting | Sep 2023 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-09-29 | 2023-09-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.